TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Prenetics Group ( (PRE) ) has provided an announcement.
On November 14, 2025, Prenetics Global Limited’s Chief Marketing Officer, Rahul Ramchand, purchased 30,000 shares of the company’s Class A Ordinary Shares at $13.29 per share, totaling $398,821. This transaction increased his total holdings to 75,553 shares, reflecting confidence in the company’s market position and potential growth.
The most recent analyst rating on (PRE) stock is a Hold with a $12.50 price target. To see the full list of analyst forecasts on Prenetics Group stock, see the PRE Stock Forecast page.
Spark’s Take on PRE Stock
According to Spark, TipRanks’ AI Analyst, PRE is a Neutral.
The overall stock score is primarily influenced by financial performance challenges, including negative profitability and cash flow issues. Technical analysis shows mixed signals, while valuation is negatively impacted by a lack of earnings and dividends. These factors collectively suggest caution for potential investors.
To see Spark’s full report on PRE stock, click here.
More about Prenetics Group
Prenetics Global Limited is a leading health sciences company, known for its premium health and longevity brand, IM8. The company operates in the health sciences industry, focusing on innovative solutions to enhance health and longevity.
Average Trading Volume: 138,147
Technical Sentiment Signal: Buy
Current Market Cap: $172.1M
For a thorough assessment of PRE stock, go to TipRanks’ Stock Analysis page.